Healthcare Sales & Marketing Network News: fluticasone

Searching News Database: fluticasone

HSMN NewsFeed - 17 Aug 2020
Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent(R) Diskus(R)
Biopharmaceuticals Drug Delivery Generics Distribution

HSMN NewsFeed - 5 Jun 2020
Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair(R) Breezhaler(R) (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 18 Mar 2020
Pharmascience Inc. Launches pms-FLUTICASONE PROPIONATE/SALMETEROL DPI for the Maintenance Treatment of Asthma and COPD
Biopharmaceuticals Generics Drug Delivery Product Launch

HSMN NewsFeed - 1 Oct 2019
Lannett Enters Into Distribution Agreement For Generic ADVAIR DISKUS(R)
Biopharmaceuticals Generics Drug Delivery Distribution

HSMN NewsFeed - 29 Jan 2018
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Nov 2017
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Nov 2017
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 20 Jul 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals

HSMN NewsFeed - 8 Feb 2017
GSK Consumer Healthcare Launches FLONASE(R) Sensimist(TM) Allergy Relief Nationwide
Biopharmaceuticals Product Launch

HSMN NewsFeed - 23 Sep 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 3 Aug 2016
FDA Approves FLONASE(R) Sensimist(TM) Allergy Relief
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jun 2016
Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Biopharmaceuticals

HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Apr 2016
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2015
OptiNose Closes New Round of Financing
Devices Drug Delivery Venture Capital

HSMN NewsFeed - 29 Jun 2015
Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Jun 2014
Theravance, Inc. Appoints George B. Abercrombie as Senior Vice President, Corporate Partnerships, Commercial
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2014
GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD
Biopharmaceuticals

HSMN NewsFeed - 14 Mar 2014
GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
Biopharmaceuticals

HSMN NewsFeed - 11 Feb 2014
Lithera Announces Final Closing of $35.6 Million Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 Nov 2013
Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 20 Sep 2013
RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Jul 2013
Lithera Announces Second Closing of $27.3 Million Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 28 Sep 2012
Seebri(R) Inhalation Capsules Receive MHLW Approval as Once-daily Maintenance Treatment for COPD in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Jul 2012
GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Jul 2012
GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD
Biopharmaceuticals

HSMN NewsFeed - 23 Mar 2012
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational Programme and Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD
Biopharmaceuticals

HSMN NewsFeed - 9 Jan 2012
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair(TM)* in COPD and Asthma
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2011
GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD
Biopharmaceuticals

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 23 Mar 2009
Skyepharma PLC Announces Regulatory Application
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2008
GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
Biopharmaceuticals

HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 21 May 2008
Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2008
FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 16 Jan 2008
Hi-Tech Pharmacal Receives Final Approval for Fluticasone Propionate Nasal Spray, 50mcg
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 8 Aug 2007
GSK Receives Decision From FDA on Advair(R) 500/50 for COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 May 2007
FDA Advisory Committee Finds Substantial Evidence to Support Advair 500/50 in Reducing COPD Exacerbations
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Apr 2007
FDA Approves Once-Daily Veramyst(TM) (fluticasone furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Children as Young as Two Years
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Apr 2007
FDA Approves Once-Daily Veramyst(TM) (fluticasone furoate) Nasal Spray for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults and Children as Young as Two Years
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 17 Oct 2006
Advair(R) HFA Inhalation Aerosol Now Available
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 11 Oct 2006
GSK Submits Supplemental Drug Application for Advair in COPD
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Sep 2006
Brian Tambi Resigns as Morton Grove Pharmaceuticals CEO
Biopharmaceuticals Generics Personnel

HSMN NewsFeed - 6 Sep 2006
SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 21 Jul 2006
Biopsy Study Shows Combination of Long-Acting Beta2-Agonist and Low Steroid Dose in Advair Diskus(R) 100/50mcg Maintains Control of Airway Inflammation
Biopharmaceuticals

HSMN NewsFeed - 3 Jul 2006
Abbott's New Tablet Formulation of Kaletra(R) (lopinavir/ritonavir) Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 23 May 2006
Ventaira Announces Positive Scintigraphy Data with Next-Generation Pulmonary Drug Delivery Device
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 8 May 2006
Kos and SkyePharma Sign Exclusive License Agreement for the Marketing and Distribution of Flutiform(TM) in the United States
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 8 May 2006
SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States
Biopharmaceuticals Licensing Distribution

Return to NewsFeed

Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 18 additional stories matching:
fluticasone
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.